Table 2 Treatment characteristics and outcome of the patients included in this series
Variable | Patients (n = 99, %) | Initial treatment | |
|---|---|---|---|
Local treatment (n = 60, 60.6%) | Observation/medical treatment (n = 39, 39.4%) | ||
Biopsy | |||
 Core needle biopsy | 70, 70.7% | 38, 63.3% | 32, 82.1% |
 Open biopsy | 29, 29.3% | 22, 36.7% | 7, 17.9% |
Total number of surgeries | |||
 Median | 1 | 1 | 0 |
 IQR | 0–1 | 1–2 | 0–0 |
NSAIDs | |||
 No | 82, 82.8% | 60, 100.0% | 22, 56.4% |
 Yes | 17, 17.2% | 0 | 17, 43.6% |
Tyrosine kinase inhibitor | |||
 No | 98, 99.0% | 60, 100.0% | 38, 97.4% |
 Yes | 1, 1.0% | 0 | 1, 2.6% |
Anti-hormonal therapy + NSAIDs | |||
 No | 87, 87.9% | 59, 98.3% | 28, 71.8% |
 Yes | 12, 12.1% | 1, 1.7% | 11, 28.2% |
Low-dose chemotherapy | |||
 No | 72, 72.7% | 56, 93.3% | 16, 41.0% |
 Yes | 27, 27.3% | 4, 6.7% | 23, 59.0% |
Follow up period (months) | |||
 Median | 57 | 58.5 | 55 |
 IQR | 33–86 | 35–96 | 27–85 |
Event | |||
 No | 71, 71.7% | 41, 68.3% | 30, 76.9% |
 Yes | 28, 28.3% | 19, 31.7% | 9, 23.1% |
Interval between the diagnosis and event | |||
 Median | 18 | 19 | 13 |
 IQR | 9–32 | 9–36 | 9–24 |
MSTS score | |||
 Median | 26 | 29 | 21 |
 IQR | 21–30 | 23–30 | 19–29.5 |